CGEN
COMPUGEN LTDPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 26 to Apr 14 ▼ 6 days of insider sells: $91.2K by 2 insiders, avg $2.34
- Apr 24 ▼ 2 insiders sell $22.4K at $3.20
- Jul 9 ▼ 1 insider sell $4.7K at $2.50
- Nov 9 ▲ Earnings: CGEN Q3 2026 Earnings: EPS $-0.06 (+26.5% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $118.3K.
- InstitutionsBEARISH
Q3 2026: 2 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
10 of 11 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.085 → −$0.087 over 90 days.
- Short sellersSTEADY
Short interest +0.5% to 2.53M shares. 9.7 days to cover, ≈2.7% of shares.
- TrendDOWNTREND
7% below its 50-day average.
- SocialQUIET
Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | TRIM | $377.2K |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $74.8K |
| JANE STREET GROUP, LLC | TRIM | $62.2K |
| BLAIR WILLIAM & CO/IL | ADD | $54.5K |
| ARK Investment Management LLC | TRIM | $1.7M |
| MILLENNIUM MANAGEMENT LLC | ADD | $560.7K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $167.2K |
| Quadrature Capital Ltd | TRIM | $63.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +96%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
| May 21, 2026 | Leerink Partners MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kredo Russo Sharon SVP, Research & Discovery Jul 29, 2026 | AWARD | 18,000 sh |
Ferre Pierre Chief Operating Officer Jul 29, 2026 | AWARD | 70,000 sh |
Ophir Eran President and CEO Jul 29, 2026 | AWARD | 200,000 sh |
Livnat Savitzky Kinneret Director Jul 29, 2026 | AWARD | 7,500 sh |
ZWEIFACH SANFORD S Director Jul 29, 2026 | AWARD | 10,000 sh |
Halevy Gilead Director Jul 29, 2026 | AWARD | 7,500 sh |
ZWEIFACH SANFORD S Director Jul 29, 2026 | AWARD | 7,500 sh |
Halevy Gilead Director Jul 29, 2026 | AWARD | 10,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.08 | -$0.10–-$0.07 | +0.0% | $3.5M |
| Next Q | -$0.09 | -$0.09–-$0.07 | No data | $466.7K |
| Current FY | -$0.30 | -$0.31–-$0.29 | +9.1% | $12.1M |
| Next FY | -$0.35 | -$0.39–-$0.31 | +4.5% | $7.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 0 bullish · 0 bearish · 9 neutral- NEUTRAL 6-KNov 9, 2026
Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3…
The narrower loss and cash runway into 2029 remove near-term financing risk. The key binary catalyst is MAIA-ovarian data in Q1 2027; positive results could validate COM701 and unlock significant…
- NEUTRAL 6-KAug 3, 2026
Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The…
This filing is a routine proxy statement with no new operational or financial disclosures. Monitor the upcoming annual meeting for any unexpected developments, but no immediate trading action is…
- NEUTRAL 6-KAug 3, 2026
Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M…
The next significant catalyst is MAIA-ovarian interim PFS data in Q1 2027. With ample cash runway, no near-term dilution expected despite $100M ATM remaining. Monitor enrollment updates and any…
- NEUTRAL EFFECTJun 9, 2026
Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective…
Monitor for any subsequent prospectus supplement or takedown announcement, which would reveal the size and pricing of an actual offering. The shelf's effectiveness itself is a routine procedural…
All CGEN filing & press-release reports (9)
- 6-K reportNov 9, 2026
- 6-K reportAug 3, 2026
- 6-K reportAug 3, 2026
- EFFECT reportJun 9, 2026
- 6-K reportMay 18, 2026
- CLUSTER reportApr 24, 2026
- CLUSTER reportApr 14, 2026
- 144 reportApr 13, 2026
- CLUSTER reportMar 26, 2026